RECURSION PHARMACEUTICALS IN's ticker is RXRX and the CUSIP is 75629V104. A total of 193 filers reported holding RECURSION PHARMACEUTICALS IN in Q3 2023. The put-call ratio across all filers is 1.13 and the average weighting 0.9%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2024 | $206,366 | -6.7% | 27,972 | +26.0% | 0.00% | – |
| Q1 2024 | $221,300 | +49.2% | 22,208 | +13.9% | 0.00% | – |
| Q2 2023 | $148,324 | +111.0% | 19,495 | +85.8% | 0.00% | – |
| Q1 2023 | $70,290 | -7.8% | 10,491 | +2.8% | 0.00% | – |
| Q4 2022 | $76,250 | -31.3% | 10,201 | 0.0% | 0.00% | – |
| Q3 2022 | $111,000 | +5.7% | 10,201 | -22.0% | 0.00% | – |
| Q2 2022 | $105,000 | – | 13,071 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Two Sigma Ventures, LP | 903,400 | $9,612,000 | 100.00% |
| Obvious Management Services, L.L.C. | 3,985,087 | $42,401,000 | 100.00% |
| DCVC Opportunity Fund II GP, LLC | 3,951,141 | $42,040,000 | 54.37% |
| Data Collective IV GP, LLC | 5,941,120 | $63,214,000 | 49.97% |
| MIC Capital Management UK LLP | 8,451,758 | $89,927,000 | 16.21% |
| MV Management XI, L.L.C. | 1,971,908 | $20,981,000 | 15.20% |
| ArchPoint Investors | 1,116,126 | $11,876,000 | 4.85% |
| HARVARD MANAGEMENT CO INC | 1,509,254 | $16,058,000 | 2.00% |
| PLATINUM INVESTMENT MANAGEMENT LTD | 2,251,971 | $23,961,000 | 1.00% |
| Duquesne Family Office | 1,385,950 | $14,747,000 | 0.84% |